Actively Recruiting
Open-label Study of a Remibrutinib and Omalizumab Treatment Approach for Adults with Chronic Spontaneous Urticaria Not Controlled by H1-Antihistamines
Led by Novartis Pharmaceuticals · Updated on 2026-10-13
382
Participants Needed
5
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new treatment approach using remibrutinib and omalizumab for adults with chronic spontaneous urticaria CSU who do not respond well to second-generation H1-antihistamines. This open-label, global, multi-center Phase 3 study aims to achieve fast and well-controlled disease within 24 weeks by assessing the safety and effectiveness of this treatment sequence. Participants will receive remibrutinib 25 mg twice daily for the first 12 weeks. After this period, those whose symptoms are well controlled UCT7 score 12 will continue remibrutinib, while participants with inadequate control UCT7 score <12 will add omalizumab 300 mg every 4 weeks. This treatment algorithm is designed to adapt based on participants response. Throughout the 24-week study, participants will complete daily urticaria symptom diaries and undergo regular assessments including urticaria activity scores and quality of life measurements. Researchers will monitor adverse events during and after treatment. The main outcome is the proportion of participants achieving low urticaria activity UAS7 6 by Week 24. Participants are expected to follow the study protocol closely and attend scheduled visits for evaluation and safety monitoring.
CONDITIONS
Brief Title
Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here